Now, CoStar is waging war against Xceligent, arguably its biggest rival. In a multimillion-dollar lawsuit, it alleged Xceligent had engaged in "copyright infringement on an industrial scale," saying that its army of researchers systematically steal CoStar's data and images. Xceligent CEO Doug Curry blasted the suit, saying it "fits with a pattern of action by CoStar of filing lawsuits against its competitors to protect its dominant market position." The firm noted that CoStar's suit comes just as Xceligent is gearing up to launch in New York, its rival's most important market. Sources told TRD 's Konrad Putzier in August that Xceligent is the only company seriously attempting to market a product similar to CoStar.